Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

100.75 +1.91 (+1.93%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

20 21 22 23 24 25 26 27 Next >

7 Insider Stocks to Buy as Execs Snap Them Up ↗

February 18, 2022

With equity prices soaring to record levels, many execs have cashed out. Here are the insider stocks where execs are cashing in.

Via InvestorPlace

Incyte to Present at Upcoming Investor Conference

February 15, 2022

From Incyte

Via Business Wire

Insiders Buy Around $112M Of 3 Stocks ↗

February 15, 2022

US stock futures traded higher on Tuesday, amid reports that some Russian troops are returning to their bases. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Oncolytics Announced Updates On Clinical Trials Of New Treatment For Triple-Negative Metastatic Breast Cancer ↗

February 10, 2022

Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Expert Ratings For Incyte ↗

February 09, 2022

Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:

Via Benzinga

Why Are Incyte Shares Trading Lower Today? ↗

February 08, 2022

Incyte Corporation's (NASDAQ: INCY)

Via Benzinga

Recap: Incyte Q4 Earnings ↗

February 08, 2022

Incyte (NASDAQ:INCY) reported its Q4 earnings results on Tuesday, February 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema ↗

January 28, 2022

Based on top-line efficacy results from two pivotal Phase 3 trials Eli Lilly And Co (NYSE: LLY) has decided to

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2022 ↗

February 09, 2022

Upgrades According to Capital One, the prior rating for Federal Realty Investment Trust (NYSE:FRT) was changed from Equal-Weight to Overweight. Federal Realty Investment...

Via Benzinga

The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar ↗

February 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs

February 08, 2022

From Incyte Corporation

Via Business Wire

Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus ↗

January 26, 2022

Incyte Corporation (NASDAQ: INCY) is

Via Benzinga

Where Incyte Stands With Analysts ↗

January 18, 2022

Within the last quarter, Incyte (NASDAQ:INCY) has observed the following an...

Via Benzinga

Earnings Scheduled For February 8, 2022 ↗

February 08, 2022

Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion.

Via Benzinga

Bear Market Bets In Biotech ↗

February 07, 2022

Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020.

Via Talk Markets

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗

February 06, 2022

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...

Via Benzinga

Incyte to Present at Upcoming Investor Conference

February 03, 2022

From Incyte

Via Business Wire

Incyte Provides Update on Parsaclisib and MCLA-145

January 25, 2022

From Incyte

Via Business Wire

Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector

January 20, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 20, 2021 – USA News Group – As the 2021 San Antonio Breast Cancer Symposium (SABCS) comes to a close, many of this year’s...

Via FinancialNewsMedia

Incyte to Report Fourth Quarter and Year-End 2021 Financial Results

January 18, 2022

From Incyte

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022 ↗

January 18, 2022

Upgrades Canaccord Genuity upgraded the previous rating for Fortuna Silver Mines Inc (NYSE:

Via Benzinga

Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019

January 14, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 14, 2022 – USA News Group – Cancer cases are on the rise, according to a new study comparing the number of cancer...

Via FinancialNewsMedia

Topics Death

This Biotech Is Working With Pfizer, Merck KGaA, Roche, and Other Leaders To Develop a Better Standard of Care for Breast Cancer ↗

January 13, 2022

Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cancer is the...

Via Benzinga

Cramer Shares His Thoughts On Incyte, Corning And More ↗

December 22, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Incyte Corporation (NASDAQ:

Via Benzinga

4 Stocks Insiders Are Buying ↗

December 20, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t...

Via Benzinga

Incyte's Topical JAK Inhibitor Under Priority FDA Review For Depigmented Skin Disorder ↗

December 15, 2021

The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) supplemental marketing application seeking approval for ruxolitinib cream 1.5% (Opzelura), a...

Via Benzinga

Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo

December 14, 2021

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conferences

December 14, 2021

From Incyte

Via Business Wire

Why Are Datadog, Zscaler, Airbnb, Fortinet, Lucid Trading Higher Premarket? ↗

December 13, 2021

Airbnb, Inc (NASDAQ: ABNB), Fortinet, Inc (NASDAQ: FTNT), Palo Alto Networks, Inc (NASDAQ: PANW), Lucid Group, Inc (NASDAQ: LCID), Zscaler, Inc (NASDAQ: ZS), and Datadog, Inc (...

Via Benzinga

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

December 11, 2021

From Incyte

Via Business Wire

< Previous 1 2

...

20 21 22 23 24 25 26 27 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Incyte Corporation - Common Stock (NQ:INCY)

All News about Incyte Corporation - Common Stock

Starting at $3.75/week.

Subscribe Today